Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer

被引：0
|
作者：
Shtivelband, Mikhail
Spigel, David R.
Gerber, David E.
Jain, Minish Mahendra
Ponomarova, Olga V.
Giorgadze, Davit
Shan, Joseph
Menander, Kerstin B.
Belani, Chandra Prakash
机构：
[1] Ironwood Canc & Res Ctr, Chandler, AZ USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Ruby Hall Clin, Pune, Maharashtra, India
[5] RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, Kiev, Ukraine
[6] Chemotherapy & Immunotherapy Clin, Tbilisi, Georgia
[7] Peregrine Pharmaceut Inc, Tustin, CA USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8095
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Kostopoulou, V
    Nikolaou, M
    Gaglia, A
    Koumpou, M
    Mylonakis, N
    Xiros, N
    Economopoulos, T
    Raptis, SA
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 294 - 299
  • [22] Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
    Chiappori, Alberto
    Bepler, Gerold
    Barlesi, Fabrice
    Soria, Jean-Charles
    Reck, Martin
    Bearz, Alessandra
    Barata, Fernando
    Scagliotti, Giorgio
    Park, Keunchil
    Wagle, Asavari
    Liepa, Astra M.
    Zhao, Yan Daniel
    Chouaki, Nadia
    Iscoe, Neill
    von Pawel, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 369 - 375
  • [23] Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
    Spigel, D. R.
    Bondarenko, I.
    Losonczy, G.
    Mezger, J.
    Kalofonos, H.
    Reck, M.
    Palmero, R.
    Jang, T.
    Natale, R.
    Sanborn, R. E.
    Lai, J.
    Kallinteris, N.
    Tang, M.
    Shan, J.
    Gerber, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] PHASE II TRIAL OF BEVACIZUMAB PLUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Ohyanagi, F.
    Kudo, K.
    Yanagitani, N.
    Horiike, A.
    Horai, T.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 441 - 442
  • [25] Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
    Ramalingam, Suresh S.
    Blais, Normand
    Mazieres, Julien
    Reck, Martin
    Jones, C. Michael
    Juhasz, Erzsebet
    Urban, Laszlo
    Orlov, Sergey
    Barlesi, Fabrice
    Kio, Ebenezer
    Keiholz, Ulrich
    Qin, Qin
    Qian, Jiang
    Nickner, Caroline
    Dziubinski, Juliann
    Xiong, Hao
    Ansell, Peter
    McKee, Mark
    Giranda, Vincent
    Gorbunova, Vera
    CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1937 - 1944
  • [26] A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin with or without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
    Dragnev, K. H.
    Attili, S. V.
    Gagua, R.
    Jain, M. M.
    Bondarenko, I.
    Shan, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S241 - S242
  • [27] Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
    Sun, Y.
    Wu, Y. -L.
    Zhou, C. -C.
    Zhang, L.
    Zhang, L.
    Liu, X. -Y.
    Yu, S. -Y.
    Jiang, G. -L.
    Li, K.
    Qin, S. -K.
    Ma, S. -L.
    Han, L.
    Quinlivan, M.
    Orlando, M.
    Zhang, X. -Q.
    LUNG CANCER, 2013, 79 (02) : 143 - 150
  • [28] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EVOFOSFAMIDE (TH-302) IN COMBINATION WITH PEMETREXED IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Goldman, J.
    Belani, C.
    Novello, S.
    von Pawel, J.
    Csoszi, T.
    Orlov, S.
    Kroll, S.
    Pearce, T.
    ANNALS OF ONCOLOGY, 2015, 26
  • [29] A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
    Raez, Luis E.
    Santos, Edgardo S.
    Webb, R. Timothy
    Wade, James
    Brito, Roger A.
    Karr, Melissa
    Kennah, Andra
    Childs, Barrett H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1103 - 1110
  • [30] A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
    Luis E. Raez
    Edgardo S. Santos
    R. Timothy Webb
    James Wade
    Roger A. Brito
    Melissa Karr
    Andra Kennah
    Barrett H. Childs
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1103 - 1110
12345